- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Medivir, GlaxoSmithKline enter co-promotion agreement
Stockholm, Sweden - Medivir has entered into a co-promotion agreement with the Swedish subsidiary of GlaxoSmithKline, according to Earthtimes.org.
Stockholm, Sweden
- Medivir has entered into a co-promotion agreement with the Swedish subsidiary of GlaxoSmithKline, according to Earthtimes.org.
The agreement will allow Medivir to co-promote some GlaxoSmithKline products on the Swedish market, such as the companies entire dermatology portfolio, including the eczema and psoriasis drug Betnovat.
The magnitude of revenue for Medivir is based on the degree that future sales exceed an agreed baseline, Earthtimes reports.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
